English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Plus monthly

Global: Zendy Tools annual

Global: Zendy Tools monthly

Global: Zendy Free Plan

A 70 years old female patient who was previously diagnosed with relapsed chronic lymphocytic leukemia was referred to our clinic with complaints of fever, dyspnea and cough. The blood count and peripheral blood smear revealed neutropenia and she was hospitalized with the diagnosis of febrile neutropenia. Patient was already on the second month of alemtuzumab therapy which was known to cause serious immunosupression. Physical examination revealed bilateral inspiratory crackles. With presumptive diagnosis of febrile neutropenia and bacterial pneumonia empirical extended spectrum antibiotic combination with antipseudomonal activity was started (piperacillin-tazobactam and ciprofloxacin). She was still febrile on the 3rd day of antibiotics and aspergillus galactomannan was 0,70 (positive). Considering that piperacilin-tazobactam may cause false positive galctomannan results, in order to eliminate a possible pulmonary aspergillosis, HRCT was performed. HRCT showed some scarce milimetric nodular consolidations with irregular margins and were surrounded by a halo with ground glass opacification (Figure 1A-BC). Liposomal amphotericin B treatment was initiated depending on the positive galactomannan and halo signs on HRCT which were thought to be related to an invasive aspergillus infection in an immunocompromized patient. In the meanwhile, bronchoscopic evaluation was requested to clarify and isolate the possible microorganism. Bronchoscopy was applied with no major complication and bronchoalveolar galactomannan was found to be 2.40 (positive). The fungal culture of bronchoalveolar lavage revealed both aspergillus fumigatus (200 cfu/ml) and aspergillus flavus (1000 cfu/ml) which were known to be sensitive to liposomal amphotericin B therapy. At the fourth day of liposomal amphotericin B treatment with appropriate dosage and administration, the fever subsided and the symptoms related to pneumonia regressed. After the third week of antifungal therapy, complete radiological response was achieved and liposomal amphotericin B was stopped at 4th week. In this immunocompromised patient, pulmonary aspergillosis, which occured after highly immunosupressive therapy with alemtuzumab, was successfully treated with appropriate antifungal therapy and did not relapse. Management of IFI in Febrile Neutropenic Patients: A Case of Invasive Aspergillosis Treated with Liposomal Amphotericin B